Answers are grounded in this paper and cite their sources.
Clinical trial demonstrates reduced central macular thickness following ziv-aflibercept in retinal vascular diseases, indicating short-term safety and anatomical efficacy.
PURPOSE: To investigate the short-term outcomes after intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. METHODS: Thirty-four eyes of 29 patients with age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO) received a single dose intravitreal injection of 0.05 ml ziv-aflibercept (1.25 mg). Visual acuity, spectral domain optical coherence tomography (SD-OCT) activity, and possible side effects were assessed before and at 1 week and 1 month after the intervention. All patients responded to treatment in terms of reduction in CMT. The improvement in visual acuity was statistically non-significant. CONCLUSION: Our findings suggest that a single dose intravitreal injection of ziv-aflibercept may have acceptable relative safety and efficacy in the treatment of patients with intraocular vascular disease. The trial was registered in the Iranian Registry of Clinical Trials (IRCT2015081723651N1).
No takes yet. Share an insight, caveat, or question.
Hodjatjalali et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: